Slow Start to Q4 Healthcare Deals

Slow Start to Q4 Healthcare Deals

by | Nov 4, 2019 2:10 pm | Healthcare Market Updates | 0 comments

October is typically a flighty month in the annual investing cycle. Spooky things can happen as the month winds down to Halloween. With the now-hot/now-not sentiments swirling around the equity markets, it was a relief not to witness a meltdown after all ended the month at or near new highs. The healthcare market wasn’t nearly so robust. Third quarter deal volume, now at 447 transactions, is still down 5% compared with the second quarter’s 471. Preliminary data for October 2019 doesn’t demonstrate a renewed vigor in the healthcare space. At 136 transactions, it is 9% lower than September deal volume, and a thumping 31% below October 2018, with 198 deals. With only one... Read More »
Ra Pharmaceuticals Targeted in $2.1 Billion Acquisition

Ra Pharmaceuticals Targeted in $2.1 Billion Acquisition

by | Oct 14, 2019 12:33 pm | Biotechnology | 0 comments

The global biopharmaceutical company UCB (Brussels: UCB) announced it is acquiring Ra Pharmaceuticals (NASDAQ: RARX) for $2.1 billion. Ra Pharma is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system. Ra Pharmaceuticals shareholders will receive $48.00 for each held share (approx. $2.5 billion or EUR 2.2 billion), with transaction value at $ 2.1 billion or EUR 2 billion, net of Ra Pharma cash. Ra Pharma reported a trailing 12-month revenue of $2.5 million. This acquisition will give UCB a number of high-value... Read More »